Lupin's Brazil subsidiary acquires 9 brands from Bausch Health

As part of the transaction, MedQu ímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle™ and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news